Please use this identifier to cite or link to this item:
|Title:||Inhibition of human cytomegalovirus replication by overexpression of CREB1||Authors:||Chia, Y.L.
Major immediate-early genes
|Issue Date:||Feb-2014||Citation:||Chia, Y.L., Ng, C.H., Lashmit, P., Chu, K.L., Lew, Q.J., Ho, J.P., Lim, H.L., Nissom, P.M., Stinski, M.F., Chao, S.-H. (2014-02). Inhibition of human cytomegalovirus replication by overexpression of CREB1. Antiviral Research 102 (1) : 11-22. ScholarBank@NUS Repository. https://doi.org/10.1016/j.antiviral.2013.11.012||Abstract:||Expression of the human cytomegalovirus (HCMV) major immediate-early (MIE) genes is regulated by a strong enhancer-containing promoter with multiple binding sites for various transcription factors, including cyclic AMP response element binding protein 1 (CREB1). Here we show that overexpression of CREB1 potently blocked MIE transcription and HCMV replication. Surprisingly, CREB1 still exhibited strong inhibition of the MIE promoter when all five CREB binding sites within the enhancer were mutated, suggesting that CREB1 regulated the MIE gene expression indirectly. Promoter deletion analysis and site-directed mutagenesis identified the region between -130 and -50 upstream of the transcription start site of the MIE gene as the "CREB1 responsive region". Mutations of SP1/3 and NF-κB binding sites within this region interrupted the inhibitory effect induced by CREB1 overexpression. Our findings suggest that overexpression of CREB1 can cause repression of HCMV replication and may contribute to the development of new anti-HCMV strategies. © 2013 Elsevier B.V. All rights reserved.||Source Title:||Antiviral Research||URI:||http://scholarbank.nus.edu.sg/handle/10635/126733||ISSN:||01663542||DOI:||10.1016/j.antiviral.2013.11.012|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 6, 2019
WEB OF SCIENCETM
checked on Nov 28, 2019
checked on Nov 29, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.